Skip to main content
Premium Trial:

Request an Annual Quote

PCR Reagents Firm Syzygy Biotech Changes Name to Empirical Bioscience


Syzygy Biotech said this week that it has changed its name to Empirical Bioscience to "better reflect its mission in serving the rapidly changing life sciences industry."

The Grand Rapids, Mich.-based company has developed a range of high-grade molecular biology products optimized for use in next-generation sequencing, translational research, agricultural applications, clinical diagnostics, and education.

More specifically, Emperical Bioscience manufactures low-cost reagents, such as Taq polymerases, and master mixes for use in DNA amplification, including the rEVAlution qPCR master mix, which it launched in November. Other offerings include its TAq 2x MeanGreen Master Mix, a ready-to-use 2x mixture of TAq DNA Polymerase, dNTPs, and buffers for efficient PCR amplification.

Empirical said it has also developed what it believes to be the most effective G-C enhancer on the market today for research of G-C rich targets, as well as a customized version for multiplexing.

In 2011 Emperical, then Syzygy, received a $100,000 investment from the Michigan Pre-Seed Capital Fund, an equity fund administered by Ann Arbor Spark that invests in tech companies to support business formation and acceleration.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.